BR0004548A - Derivados i de quinolin-4-ila - Google Patents

Derivados i de quinolin-4-ila

Info

Publication number
BR0004548A
BR0004548A BR0004548-9A BR0004548A BR0004548A BR 0004548 A BR0004548 A BR 0004548A BR 0004548 A BR0004548 A BR 0004548A BR 0004548 A BR0004548 A BR 0004548A
Authority
BR
Brazil
Prior art keywords
lower alkyl
phenyl
amino
aminobutanol
quinolinyl
Prior art date
Application number
BR0004548-9A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0004548A publication Critical patent/BR0004548A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS I DE QUINOLIN-4-ILA"<D>. A invenção refere-se a compostos de fórmula onde R^ 1^ é hidrogênio, alquila inferior, alcóxi inferior, hidróxi, amino, nitro, ciano, alquil-amino inferior, di-alquil-amino inferior ou halogênio; R^ 2^ é fenila, optativamente substituída por alquila inferior, alcóxi inferior, halogênio, trifluorometila, amino, alquil-amino inferior ou di-alquil-amino inferior, 2,3-dihidro-benzofuran-5-ila, croman-6-ila, naftalen-2-ila, indano-5-ila, alquil-fenila inferior, 5,6,7,8-tetrahidro-naftalenila, 2,3-dihidro-isoindol-2-ila, 1,2,3,4-tetrahidro-naftalenila, benzofuran-2-ila, benzo[b]tiofen-2-ila, alquil-fenila inferior, 3,4-dihidro-1H-isoquinolin-2-ila ou tiofen-3-ila; R^ 3^ e R^ 4^ são independentemente de cada um hidrogênio ou alquila inferior; R^ 5^ é hidrogênio, alquila inferior, -CH~ 2~OH ou -CH~ 2~NR^ 6^R^ 7^; R^ 6^ e R^ 7^ são independentemente de cada um hidrogênio, alquila inferior, -(CH~ 2~)~ n~-fenila, cicloalquila, -(CH~ 2~)~ m~-morfolinila ou formam juntos com átomo N um anel saturado com 4-6 átomos de C; n é 0-3; m é 2-3; X é -NR^ 8^- ou -O-; ou X e R^ 5^ são juntos >N(CH~ 2~)~ 2~-; ou X e R^ 3^ são juntos >N(CH~ 2~)~ 3~-; e R^ 8^ é hidrogênio ou alquila inferior; e para sais de adição de ácido aceitáveis farmaceuticamente do mesmo, com exceção dos compostos seguintes (6-Cloro-2-fenil-4-quinolinil)-(+)-2-aminobutanol; (6-metil-2-fenil-4-quinolinil)-(+)-2-aminobutanol; (6-metóxi-2-fenil-4-quinolinil)-(+)-2-aminobutanol; e (8-metóxi-2-fenil-4-quinolinil)-(+)-2-aminobutanol; o qual pode ser usado para o tratamento de doenças, as quais referem-se aos bloqueadores específicos de receptores de NMDA.
BR0004548-9A 1999-10-01 2000-09-29 Derivados i de quinolin-4-ila BR0004548A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119539 1999-10-01

Publications (1)

Publication Number Publication Date
BR0004548A true BR0004548A (pt) 2001-05-29

Family

ID=8239107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004548-9A BR0004548A (pt) 1999-10-01 2000-09-29 Derivados i de quinolin-4-ila

Country Status (26)

Country Link
US (1) US6440995B1 (pt)
JP (1) JP3523174B2 (pt)
KR (1) KR100398561B1 (pt)
CN (1) CN1181059C (pt)
AR (1) AR025882A1 (pt)
AT (1) ATE281436T1 (pt)
AU (1) AU774363B2 (pt)
BR (1) BR0004548A (pt)
CA (1) CA2321324A1 (pt)
CO (1) CO5200789A1 (pt)
CZ (1) CZ20003575A3 (pt)
DE (1) DE60015471T2 (pt)
ES (1) ES2230017T3 (pt)
HR (1) HRP20000639A2 (pt)
HU (1) HUP0003861A3 (pt)
ID (1) ID27525A (pt)
IL (1) IL138777A0 (pt)
MA (1) MA26752A1 (pt)
NO (1) NO20004892L (pt)
NZ (1) NZ507141A (pt)
PE (1) PE20010648A1 (pt)
PL (1) PL342876A1 (pt)
PT (1) PT1088818E (pt)
SG (1) SG164268A1 (pt)
TR (1) TR200002831A3 (pt)
ZA (1) ZA200005239B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
PL372488A1 (en) * 2002-02-13 2005-07-25 F.Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
EP2215074B1 (en) * 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
ES2769648T3 (es) * 2014-06-16 2020-06-26 Fundacion Para La Investig Medica Aplicada Nuevos compuestos como inhibidores duales de histona metiltransferasas y ADN metiltransferasasASAS
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
KR20170074178A (ko) * 2015-12-21 2017-06-29 제이엔씨 주식회사 중합성 액정 화합물, 조성물, 그 액정 중합막류 및 이들의 용도
CN105646462B (zh) * 2016-01-19 2019-04-05 河南大学 芸香宁碱衍生物、其制备方法及应用
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE440008C (de) 1924-03-29 1927-05-04 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Chinolinderivaten
US4560692A (en) 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5441963A (en) 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
PE20010648A1 (es) 2001-06-13
AU6132400A (en) 2001-04-05
CA2321324A1 (en) 2001-04-01
NO20004892L (no) 2001-04-02
NO20004892D0 (no) 2000-09-29
US6440995B1 (en) 2002-08-27
IL138777A0 (en) 2001-10-31
DE60015471T2 (de) 2005-10-27
AU774363B2 (en) 2004-06-24
DE60015471D1 (de) 2004-12-09
TR200002831A2 (tr) 2001-04-20
ES2230017T3 (es) 2005-05-01
PL342876A1 (en) 2001-04-09
HUP0003861A2 (hu) 2001-10-28
HUP0003861A3 (en) 2002-09-30
ATE281436T1 (de) 2004-11-15
JP2001097952A (ja) 2001-04-10
SG164268A1 (en) 2010-09-29
AR025882A1 (es) 2002-12-18
CN1290698A (zh) 2001-04-11
CZ20003575A3 (cs) 2001-11-14
HRP20000639A2 (en) 2001-06-30
HU0003861D0 (en) 2000-12-28
ID27525A (id) 2001-04-12
PT1088818E (pt) 2005-03-31
JP3523174B2 (ja) 2004-04-26
KR20010050738A (ko) 2001-06-15
TR200002831A3 (tr) 2001-04-20
MA26752A1 (fr) 2004-12-20
ZA200005239B (en) 2001-04-16
KR100398561B1 (ko) 2003-09-19
CN1181059C (zh) 2004-12-22
CO5200789A1 (es) 2002-09-27
NZ507141A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
PT870768E (pt) Derivados azaindole-etilamina como agentes de ligacao nicotinicos aos receptores de acetilcolina
LU92113I2 (fr) Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA)
ATE253051T1 (de) Chinolinderivate und chinazolinderivate
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
EA200300619A1 (ru) Серотонинергические средства
BR0009278A (pt) 1-arenossulfonil-2-aril-pirrolidina e derivados depiperidina
BR0004548A (pt) Derivados i de quinolin-4-ila
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
BR0213177A (pt) Derivados de 5-metóxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
BR0115480A (pt) Derivados de pirimidina
DE60002583D1 (de) Benzofurylpiperazine als serotonin-agonisten
NZ519126A (en) Novel IL-8 receptor antagonists
BRPI0414460A (pt) compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso
BR0212839A (pt) Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes e composição farmacêutica contendo os mesmos
BR9911843A (pt) 4 5 6 7-indol e derivados de indolina, preparação e utilização dos mesmos
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
DK1140925T3 (da) 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3-yl)-alkylaminer]-aminer
BR0212990A (pt) Sais farmacêuticamente aceitáveis de camptotecinas
BR0010213A (pt) Derivados de ciclocarbamato como moduladores de receptor de progesterona
BR9910859A (pt) Derivados de cianoiminoquinoxalina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A , 10A E 11A ANUI DADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.